VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and…
Author: Business Wire
GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the U.S…
GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Thyroid Eye Disease (TED) Treatments Market Nears $4.3 Billion by 2032: Emerging Small Molecule Therapies Targeting Orbital Fibroblasts Drive Revenue Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Thyroid Eye Disease Treatments Market – Global Forecast 2025-2032” report has been added to ResearchAndMarkets.com’s offering. The thyroid eye disease treatments market is undergoing substantial transformation, fueled by n…
Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today responded to the fourth po…
Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right under the Alcon merger agreement to require STAAR t…
Ollin Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases, today announced that Jason Ehrlich, M.D., Ph.D….
Bausch + Lomb Announces Two Board of Directors Appointments
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C. Alfonso, MD, and Steven H. Collis have been appoin…
Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood,…
STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following open letter to STAAR stockhol…
Future Forward Labs Appoints Dr. Delia DeBuc as Applied Science Mentor to Advance Applied Physics and Biomedical Innovation
SEATTLE–(BUSINESS WIRE)– #highschool–Future Forward Labs today announced the appointment of Dr. Delia DeBuc as STEM Mentor – Applied Physics and Biomedical Science. Dr. DeBuc brings more than 20 years of multidisciplinary research, scientific leader…
Dompé verabreicht Isocyclosporin an erste Patienten einer Phase-3-Studie in Europa und den USA für die Indikation atopische Keratokonjunktivitis
MAILAND und SAN MATEO, Kalifornien, USA–(BUSINESS WIRE)–Dompé, ein führendes Biopharmaunternehmen mit Niederlassungen in Italien und den USA, meldete die Aufnahme der ersten Patienten in eine Phase-3-Studie zu Isocyclosporin für die Behandlung von at…
Dompé behandelt eerste patiënten in Europa en de VS in fase 3-onderzoek naar isocyclosporine voor atopische keratoconjunctivitis
MILAAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, een toonaangevend biofarmaceutisch bedrijf met activiteiten in Italië en de VS, heeft aangekondigd dat de eerste patiënten zijn ingeschreven voor een fase 3-onderzoek naar isocyclosporine voor de beha…
Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
HONG KONG–(BUSINESS WIRE)–Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today re…
Dompé somministra le dosi ai primi pazienti in Europa e negli Stati Uniti nello studio di fase 3 sull'isociclosporina per la cheratocongiuntivite atopica
MILANO e SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, un’azienda biofarmaceutica leader con sedi operative in Italia e negli Stati Uniti, oggi ha annunciato l’arruolamento dei primi pazienti in uno studio di fase 3 sulla isociclosporina per il trattament…
Dompé administre les premières doses à des patients en Europe et aux États-Unis dans le cadre d'une étude de Phase 3 sur l'isocyclosporine pour traiter la kératoconjonctivite atopique
MILAN et SAN MATEO, Californie–(BUSINESS WIRE)–Dompé, une société biopharmaceutique de premier plan implantée en Italie et aux États-Unis, annonce que les premiers patients ont été admis dans une étude de Phase 3 sur l’isociclosporine sur le traiteme…
Dompé somministra le dosi ai primi pazienti in Europa e negli Stati Uniti nello studio di fase 3 sull'isociclosporina per la cheratocongiuntivite atopica
MILANO e SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, un’azienda biofarmaceutica leader con sedi operative in Italia e negli Stati Uniti, oggi ha annunciato l’arruolamento dei primi pazienti in uno studio di fase 3 sulla isociclosporina per il trattament…
Dompé administre les premières doses à des patients en Europe et aux États-Unis dans le cadre d'une étude de Phase 3 sur l'isocyclosporine pour traiter la kératoconjonctivite atopique
MILAN et SAN MATEO, Californie–(BUSINESS WIRE)–Dompé, une société biopharmaceutique de premier plan implantée en Italie et aux États-Unis, annonce que les premiers patients ont été admis dans une étude de Phase 3 sur l’isociclosporine sur le traiteme…
Dompé inicia en Europa y Estados Unidos un estudio de fase 3 de isociclosporina en pacientes con queratoconjuntivitis atópica
MILÁN y SAN MATEO, California–(BUSINESS WIRE)–Dompé, empresa biofarmacéutica líder con operaciones en Italia y Estados Unidos, ha anunciado el inicio de la inclusión de los primeros pacientes en un estudio de fase 3 de isociclosporina para el tratami…